Cargando…

Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study

AIMS: Abuse of anabolic androgenic steroids (AAS) is highly prevalent among male recreational athletes. The objective of this study was to investigate the impact of AAS abuse on reproductive hormone levels and symptoms suggestive of hypogonadism in current and former AAS abusers. METHODS: This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasmussen, Jon Jarløv, Selmer, Christian, Østergren, Peter Busch, Pedersen, Karen Boje, Schou, Morten, Gustafsson, Finn, Faber, Jens, Juul, Anders, Kistorp, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988681/
https://www.ncbi.nlm.nih.gov/pubmed/27532478
http://dx.doi.org/10.1371/journal.pone.0161208
_version_ 1782448460612501504
author Rasmussen, Jon Jarløv
Selmer, Christian
Østergren, Peter Busch
Pedersen, Karen Boje
Schou, Morten
Gustafsson, Finn
Faber, Jens
Juul, Anders
Kistorp, Caroline
author_facet Rasmussen, Jon Jarløv
Selmer, Christian
Østergren, Peter Busch
Pedersen, Karen Boje
Schou, Morten
Gustafsson, Finn
Faber, Jens
Juul, Anders
Kistorp, Caroline
author_sort Rasmussen, Jon Jarløv
collection PubMed
description AIMS: Abuse of anabolic androgenic steroids (AAS) is highly prevalent among male recreational athletes. The objective of this study was to investigate the impact of AAS abuse on reproductive hormone levels and symptoms suggestive of hypogonadism in current and former AAS abusers. METHODS: This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95%CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. All participants were aged 18–50 years and were involved in recreational strength training. Reproductive hormones (FSH, LH, testosterone, inhibin B and anti-Müllerian hormone (AMH)) were measured using morning blood samples. Symptoms of hypogonadism (depressive symptoms, fatigue, decreased libido and erectile dysfunction) were recorded systematically. RESULTS: Former AAS abusers exhibited significantly lower median (25(th) –75(th) percentiles) total and free testosterone levels than control participants (total testosterone: 14.4 (11.9–17.7) nmol/l vs. 18.8 (16.6–22.0) nmol/l) (P < 0.01). Overall, 27.2% (13.3; 45.5) of former AAS abusers exhibited plasma total testosterone levels below the lower reference limit (12.1 nmol/l) whereas no control participants exhibited testosterone below this limit (P < 0.01). Gonadotropins were significantly suppressed, and inhibin B and AMH were significantly decreased in current AAS abusers compared with former AAS abusers and control participants (P < 0.01). The group of former AAS abusers had higher proportions of participants with depressive symptoms ((24.2%) (11.1; 42.2)), erectile dysfunction ((27.3%) (13.3; 45.6)) and decreased libido ((40.1%) (23.2; 57.0)) than the other two groups (trend analyses: P < 0.05). CONCLUSIONS: Former AAS abusers exhibited significantly lower plasma testosterone levels and higher frequencies of symptoms suggestive of hypogonadism than healthy control participants years after AAS cessation. Current AAS abusers exhibited severely decreased AMH and inhibin B indicative of impaired spermatogenesis.
format Online
Article
Text
id pubmed-4988681
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49886812016-08-29 Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study Rasmussen, Jon Jarløv Selmer, Christian Østergren, Peter Busch Pedersen, Karen Boje Schou, Morten Gustafsson, Finn Faber, Jens Juul, Anders Kistorp, Caroline PLoS One Research Article AIMS: Abuse of anabolic androgenic steroids (AAS) is highly prevalent among male recreational athletes. The objective of this study was to investigate the impact of AAS abuse on reproductive hormone levels and symptoms suggestive of hypogonadism in current and former AAS abusers. METHODS: This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95%CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. All participants were aged 18–50 years and were involved in recreational strength training. Reproductive hormones (FSH, LH, testosterone, inhibin B and anti-Müllerian hormone (AMH)) were measured using morning blood samples. Symptoms of hypogonadism (depressive symptoms, fatigue, decreased libido and erectile dysfunction) were recorded systematically. RESULTS: Former AAS abusers exhibited significantly lower median (25(th) –75(th) percentiles) total and free testosterone levels than control participants (total testosterone: 14.4 (11.9–17.7) nmol/l vs. 18.8 (16.6–22.0) nmol/l) (P < 0.01). Overall, 27.2% (13.3; 45.5) of former AAS abusers exhibited plasma total testosterone levels below the lower reference limit (12.1 nmol/l) whereas no control participants exhibited testosterone below this limit (P < 0.01). Gonadotropins were significantly suppressed, and inhibin B and AMH were significantly decreased in current AAS abusers compared with former AAS abusers and control participants (P < 0.01). The group of former AAS abusers had higher proportions of participants with depressive symptoms ((24.2%) (11.1; 42.2)), erectile dysfunction ((27.3%) (13.3; 45.6)) and decreased libido ((40.1%) (23.2; 57.0)) than the other two groups (trend analyses: P < 0.05). CONCLUSIONS: Former AAS abusers exhibited significantly lower plasma testosterone levels and higher frequencies of symptoms suggestive of hypogonadism than healthy control participants years after AAS cessation. Current AAS abusers exhibited severely decreased AMH and inhibin B indicative of impaired spermatogenesis. Public Library of Science 2016-08-17 /pmc/articles/PMC4988681/ /pubmed/27532478 http://dx.doi.org/10.1371/journal.pone.0161208 Text en © 2016 Rasmussen et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rasmussen, Jon Jarløv
Selmer, Christian
Østergren, Peter Busch
Pedersen, Karen Boje
Schou, Morten
Gustafsson, Finn
Faber, Jens
Juul, Anders
Kistorp, Caroline
Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study
title Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study
title_full Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study
title_fullStr Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study
title_full_unstemmed Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study
title_short Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study
title_sort former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case-control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988681/
https://www.ncbi.nlm.nih.gov/pubmed/27532478
http://dx.doi.org/10.1371/journal.pone.0161208
work_keys_str_mv AT rasmussenjonjarløv formerabusersofanabolicandrogenicsteroidsexhibitdecreasedtestosteronelevelsandhypogonadalsymptomsyearsaftercessationacasecontrolstudy
AT selmerchristian formerabusersofanabolicandrogenicsteroidsexhibitdecreasedtestosteronelevelsandhypogonadalsymptomsyearsaftercessationacasecontrolstudy
AT østergrenpeterbusch formerabusersofanabolicandrogenicsteroidsexhibitdecreasedtestosteronelevelsandhypogonadalsymptomsyearsaftercessationacasecontrolstudy
AT pedersenkarenboje formerabusersofanabolicandrogenicsteroidsexhibitdecreasedtestosteronelevelsandhypogonadalsymptomsyearsaftercessationacasecontrolstudy
AT schoumorten formerabusersofanabolicandrogenicsteroidsexhibitdecreasedtestosteronelevelsandhypogonadalsymptomsyearsaftercessationacasecontrolstudy
AT gustafssonfinn formerabusersofanabolicandrogenicsteroidsexhibitdecreasedtestosteronelevelsandhypogonadalsymptomsyearsaftercessationacasecontrolstudy
AT faberjens formerabusersofanabolicandrogenicsteroidsexhibitdecreasedtestosteronelevelsandhypogonadalsymptomsyearsaftercessationacasecontrolstudy
AT juulanders formerabusersofanabolicandrogenicsteroidsexhibitdecreasedtestosteronelevelsandhypogonadalsymptomsyearsaftercessationacasecontrolstudy
AT kistorpcaroline formerabusersofanabolicandrogenicsteroidsexhibitdecreasedtestosteronelevelsandhypogonadalsymptomsyearsaftercessationacasecontrolstudy